These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 20714145

  • 1. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections.
    Jia B, Lu P, Huang W, Li C, Huang A, Zhou X, Zhang W, Wu G, Zhang G.
    Chemotherapy; 2010; 56(4):285-90. PubMed ID: 20714145
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.
    Hou F, Li J, Wu G, Zheng B, Chen Y, Gu J, Wang H, Huo L, Xue X, Jia C, Yin Y, Tian X, Ren S.
    Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
    Hou F, Wu G, Zheng B.
    Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M, Mariyanovski V, McLeroth P, Akers W, Lee YC, Brown ML, Du J, Pedley A, Kartsonis NA, Paschke A.
    J Antimicrob Chemother; 2017 Sep 01; 72(9):2616-2626. PubMed ID: 28575389
    [Abstract] [Full Text] [Related]

  • 9. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI, Fung CP, Liu CY.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May 01; 63(5):361-7. PubMed ID: 10862445
    [Abstract] [Full Text] [Related]

  • 10. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A, Strohmeyer M, Corti G, Buonomini MI, Franchino L, Romanelli G, Moretti AM, De Vizzi GB, Petraglia A, Mancini P, Atzeni R, Fogliani V, Giura R, Paradisi F.
    Drugs Exp Clin Res; 1999 May 01; 25(6):243-52. PubMed ID: 10713862
    [Abstract] [Full Text] [Related]

  • 11. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC, File TM, Embil JM, Krige JE, Klein S, Rose A, Melnick D, Soto NE.
    Surg Infect (Larchmt); 2005 May 01; 6(3):269-82. PubMed ID: 16201937
    [Abstract] [Full Text] [Related]

  • 12. The efficacy and safety of imipenem/cilastatin in the treatment of severe bacterial infections.
    D'Amato C, Armignacco O, Antonucci G, Bordi E, Bove G, De Carli G, De Mori P, Rosci MA, Visco G.
    J Chemother; 1990 Apr 01; 2(2):100-7. PubMed ID: 2193998
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Imipenem/cilastatin: general experience in a community hospital.
    Iannini PB, Kunkel MJ, Hilton E, Iannini GM.
    Am J Med; 1985 Jun 07; 78(6A):122-6. PubMed ID: 3859211
    [Abstract] [Full Text] [Related]

  • 15. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
    Garau J, Blanquer J, Cobo L, Corcia S, Daguerre M, de Latorre FJ, León C, Del Nogal F, Net A, Rello J.
    Eur J Clin Microbiol Infect Dis; 1997 Nov 07; 16(11):789-96. PubMed ID: 9447899
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy and tolerability of imipenem/cilastatin in infections at various sites].
    Grassi C, Baglioni A, Bonsignore G, Catena E, De Rose V, Grignani F, Lotti T, Orlandi O, Panichi G, Pavone Macaluso M.
    G Ital Chemioter; 1986 Nov 07; 33(2-3):143-8. PubMed ID: 3479372
    [No Abstract] [Full Text] [Related]

  • 17. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.
    Naber KG, Savov O, Salmen HC.
    Int J Antimicrob Agents; 2002 Feb 07; 19(2):95-103. PubMed ID: 11850161
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial.
    Wang X, Zhang X, Zong Z, Yu R, Lv X, Xin J, Tong C, Hao Q, Qin Z, Xiong Y, Liu H, Ding G, Hu C, Biapenem Study Collaborative Group.
    Indian J Med Res; 2013 Dec 07; 138(6):995-1002. PubMed ID: 24521647
    [Abstract] [Full Text] [Related]

  • 20. Imipenem/cilastatin therapy for serious infections in neonates and infants.
    Nalin DR, Jacobsen CA.
    Scand J Infect Dis Suppl; 1987 Dec 07; 52():46-55. PubMed ID: 3331042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.